Boston makes hostile bid for Guidant but Johnson & Johnson won't rise to the bait
This article was originally published in Clinica
Executive Summary
In what has been described by analysts as a "gutsy" move, Boston Scientific this week attempted to upstage one of the biggest healthcare giants by moving in on its acquisition target, writes Tina Tan. The Natick, Massachusetts-based medical device firm offered to buy Guidant for a consideration of $25bn, some $3.5bn more than Johnson & Johnson's revised offer for the cardiology company, announced last month.